Dapagliflozin showed no clear reduction in heart attack size
The median cumulative measure of a heart-injury blood marker over 72 hours was 2,812,946 with dapagliflozin versus 3,046,243 with placebo.
Double-blind, placebo-controlled
Limit: The trial included only 60 patients
Edited by Boris Djordjevic · AgingResearch.News
The randomized, double-blind trial enrolled 60 people with ST-elevation myocardial infarction, a type of heart attack, who presented within 12 hours of symptom onset. Their average age was 63.9 years, and 66.7% were men. All qualified for an urgent procedure to reopen a blocked heart artery. Participants received either dapagliflozin—20 mg before the artery was reopened, followed by 10 mg daily for three months—or placebo.
Researchers measured troponin I, a blood marker of heart muscle injury, over 72 hours to estimate heart attack size. Dapagliflozin did not significantly reduce this measure. Among patients with repeat magnetic resonance heart scans, reductions in damaged heart muscle were numerically greater with dapagliflozin at 12 weeks, but the differences were not statistically significant.
Why it matters
Heart attacks are a concern for health in later life. The trial addressed whether giving dapagliflozin before blood flow returned could limit heart muscle injury.
Caveats
The trial included only 60 patients who presented within 12 hours and qualified for urgent artery reopening. This conference abstract did not report adverse events or how many patients had repeat heart scans.
